Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
Daiichi Sankyo
2020-09-25 15:05:55
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020
Daiichi Sankyo
2020-09-18 10:07:46
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer
Daiichi Sankyo
2020-09-15 15:08:35
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced
Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual Meeting
Daiichi Sankyo
2020-09-09 15:51:20
Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA (edoxaban) during routine clinical care
Daiichi Sankyo
2020-09-01 10:19:50
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and
NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during 2.5 years of treatment
Daiichi Sankyo
2020-08-28 11:00:00
NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during
ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights important clinical considerations for treating elderly patients with atrial fibrillation
Daiichi Sankyo
2020-08-28 11:04:16
ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Daiichi Sankyo
2020-08-03 09:16:13
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi
Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban treatment
Daiichi Sankyo
2020-08-28 11:06:49
Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer
Daiichi Sankyo
2020-08-28 11:07:47
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive
